HIV InfectionEarly Phase 1PrEP-IndiaNCT02148094
Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India
A Early Phase 1 study testing Truvada in people with HIV Infection, run by University of Manitoba at 2 sites in India.
Trial summary
Female sex workers (FSWs) in India are at high risk of HIV infection, and while correct and consistent condom use is an effective means of preventing HIV transmission, many FSWs have difficulty insisting on their use. Read more about this study
- Who is it for?
- Ages 18 to 49 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- HIV Infection
- What is being tested?
- Truvada
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,325 participants
- Where
- 2 sitesIndia
- Study dates
- Jan 2016to 30 Jun 2018
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Self-identification as a current FSW
- Age 18 and older
- Self-reported interest in and willingness to take PrEP
- Score cutoff on risk screening tool / PrEP indication tool
- HIV-negative test at time of enrollment (per testing algorithm)
- No clinical signs of acute HIV infection
Show all 11Show fewer
- Hepatitis-B virus antigen negative (upon screening)
- Creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula) (upon screening)
- Not currently taking PrEP or enrolled in another PrEP demonstration project
- Negative urine pregnancy test at time of enrollment
- Lives within the catchment area of the project site and no plans to move away from the project area in the next 16 months
Who cannot join
- Under 18
- Does not meet inclusion criteria
Trial locations and contacts
2 sites in 1 country.
India2 sites
DMSC Clinic
Kolkata, West Bengal
Ashodaya Samithi clinic
Mysore, Karnataka
About this study
Official title: Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India
Female sex workers (FSWs) in India are at high risk of HIV infection, and while correct and consistent condom use is an effective means of preventing HIV transmission, many FSWs have difficulty insisting on their use. Alternative HIV prevention options are needed for FSWs who are unable to correctly and consistently use condoms with their clients or regular partners. Oral pre-exposure prophylaxis (PrEP) may be an important tool to fill this critical prevention gap, and a demonstration project is required to assess the impact and feasibility of the use of PrEP as an HIV prevention intervention among most at risk FSWs in India.
The proposed project will take place at two sites in India and will assess the use of a risk assessment tool to identify FSWs who would most benefit from PrEP, collect information about the reasons why FSWs choose to accept or decline PrEP, evaluate two different PrEP delivery strategies (weekly clinic pick-up or home delivery by peer educators every second day), monitor adherence to and discontinuation of PrEP, and evaluate unintended consequences of the use of PrEP in these communities (e.g. reduction of condom use, drug side effects or adverse events, social harms or resistance). To ensure the safety of study participants, a community advisory board will be set up and will meet regularly to inform study staff of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner. A data safety and monitoring board will also be established to monitor participant safety.
Read the detailed description
This PrEP demonstration study is designed to assess the feasibility and impact of delivering PrEP in addition to the existing package of HIV prevention interventions available to female sex workers in India. The study aims to: 1) identify female sex workers in need of HIV prevention and willing to take PrEP; 2) evaluate sustained uptake and adherence to oral PrEP; 3) assess safe delivery of PrEP; and 4) demonstrate effective delivery of PrEP within the context of the National Program of Targeted Interventions. The study will be implemented in two regions and among two typologies of female sex workers in India: brothel-based FSWs in Kolkata and FSWs operating from different settings in Mysore and Mandya.
Outcome 1: Identification of female sex workers in need of HIV prevention and willing to take oral PrEP For optimal delivery with limited resources, it is critical to provide HIV prevention strategies such as PrEP to populations at greatest risk of infection. Female sex workers are an important population for HIV prevention in India, prioritized as a "core high risk group" for targeted interventions by the India National AIDS Control Organization (NACO) (NACO 2013 annual report). In particular, some FSWs report inconsistent condom use and have unmet needs for HIV prevention (Ramesh, 2010; Reza-Paul, 2008). For example, these women may be less empowered or able to consistently demand condom use by their clients or may wish to become pregnant. PrEP has the potential to be an additional, more acceptable and effective HIV prevention method for female sex workers who have difficulty using condoms consistently.
This study proposes the development and use of a risk screening tool to identify female sex workers who are most vulnerable to HIV. This tool will guide recruitment into the demonstration study and could later assist health providers in deciding who will benefit most from PrEP for HIV prevention. In addition, this study will assess the proportion of FSWs identified by the risk screening tool who are willing to take PrEP. Quantitative and qualitative evaluations will identify factors related to the decision to initiate PrEP as well as reasons why FSWs decline PrEP.
Outcome 2: Sustained uptake and adherence to oral PrEP among female sex workers Similar to all medications, sustained uptake and adherence to PrEP is fundamental for efficacy in preventing HIV acquisition. In the four clinical trials of oral PrEP that demonstrated efficacy, study participants with high adherence had the greatest protection from HIV (Baeten 2012, Choopanya 2013, Grant 2010, Thigpen 2012). Likewise, across PrEP trials, there was a clear relationship between higher efficacy and a greater proportion of participants with study drug detectable in their blood. Two randomized clinical trials of daily oral PrEP among heterosexual women in Africa found no efficacy for HIV prevention; poor adherence to PrEP most likely explains these results (Marrazzo 2013, Van Damme 2012). For example, drug level testing in the FEM-PrEP Study found that less than 40% of a random sample of HIV negative women in the PrEP arm of the study had detectable levels of PrEP in their blood (Van Damme 2012). Analyses of high-risk subgroups of study participants in the Partners PrEP Study found PrEP efficacy estimates ranged from 64 to 84%, showing consistently high efficacy of PrEP in preventing HIV across various higher risk groups, including women (Murnane 2013).
Preliminary community awareness campaigns for PrEP among female sex workers in Kolkata found high interest in PrEP - approximately 80% reported willingness to take daily, oral PrEP. Sex workers in Mysore-Mandya are engaged in series of consultations where information related to PrEP as a tool for combination prevention is being discussed and questions or concerns related to PrEP addressed. In both places, initial observations show that there are some sex workers (e.g. those who are on long time contracts, those with overnight clients where sometimes the number of clients are not disclosed, those who want to be pregnant, and those who do not use condoms with their regular partners) expressed interest in being part of the demonstration project.
This PrEP demonstration study will assess the acceptability and feasibility of two approaches to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up. Study staff will measure PrEP initiation, adherence and discontinuation. They will record these events in participant records, and quarterly visits will be used to assess adherence through biological tests and questionnaires. PrEP will be delivered as part of a package of HIV prevention services, and therefore use of other prevention strategies, such as condom use, will also be monitored. The full package of prevention services will continue to be provided to FSWs with the support of India's national government and in accordance with national guidelines.
Data on drug adherence and condom use will be collected through various means. An ethnographic study will be designed to understand factors that may promote or impede adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In addition to this, peer educators will use a pictorial tool to document these items (e.g., frequency and patterns of sexual activity, condom use, and PrEP use). The study will also include a biological measure of PrEP adherence through the assessment of drug-levels in the blood.
Regular counselling about HIV prevention and PrEP will be provided to study participants to promote adherence. In a sub-sample of study participants, an electronic adherence monitoring device to measure and promote adherence, Helping Hands, will be tested (De Blaser 2010). The Helping Hands device is complimented by a web platform that illustrates patient-specific data to monitor dosing history and adherence patterns.
Outcome 3: Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers Four randomized controlled trials have demonstrated that daily, oral PrEP is safe for HIV-uninfected women in a wide range of settings; these antiretrovirals have been proven safe for HIV-infected women for many years of use. The most common side effects of FTC/TDF are minor and short-lived (i.e. first several weeks). This study will provide evidence for the safe delivery of oral PrEP to female sex workers in brothel and street-based settings in India. Quarterly clinic visits will assess physical health, side effects, adverse events and any other social harms or concerns with PrEP use. This study will invest in continuous engagement with communities of female sex workers according to good participatory practice guidelines to provide correct information about PrEP, keep communities continuously engaged, and maintain adherence to PrEP.
A community advisory board (CAB) and a Data Safety and Monitoring Board (DSMB) will be set up. The CAB will meet monthly and on an as needed basis. It will inform study staff of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner. The CAB members will be close to the community and will be able to respond to community concerns by calling meetings to address issues in a timely manner. The DSMB will be set up to ensure that the rights of the study participants are safeguarded in a transparent fashion, and to monitor their safety by scrutinizing any adverse events. The DSMB will also help to respond to concerns raised by the CAB. The DSMB will include an ethicist, a human rights lawyer, representatives from University of Manitoba, WHO and UNAIDS, representatives from the global network of sex workers, and a statistician. In addition, ongoing qualitative research and monitoring by research staff, as well as outreach by peer educators, will attempt to identify any community resistance, rumours or actual harms, and respond in an appropriate manner.
Outcome 4: Effective delivery of oral HIV PrEP demonstrated in context of National Program of Targeted Interventions This study proposes to deliver PrEP within the context of the National Program of Targeted Interventions in order to demonstrate that PrEP is feasible in "real world" settings. DMSC and Ashodaya currently implement targeted intervention programs for female sex workers in Kolkata and Mysore/Mandya, respectively. These programs provide outreach by peer educators and outreach workers, clinic services (e.g. HIV testing and counseling, STI screening and treatment), and referrals for HIV care and treatment for brothel- and street-based FSWs. This study will evaluate the addition of PrEP to this existing service delivery model. It will also show willingness of participants to enroll in a demonstration study and to use oral PrEP without reimbursements or incentives for participation.
Study findings can inform national and local government's decision to adopt PrEP as a new HIV prevention strategy. Development of HIV prevention packages, provider training, quality management and service delivery guidelines in line with national systems will provide guidance for real life implementation of PrEP, and also contribute to the larger goal of providing standards for the delivery of HIV prevention interventions.
Risk Mitigation Identification of willing participants: The development of a tool to correctly identify those FSWs at continued risk of HIV infection does not ensure that those women will be willing to take PrEP. Though initial interest in PrEP is strong in Sonagachi among FSWs in general, women at highest risk may be different. A feasibility study to identify levels of awareness about PrEP, perceptions and misconceptions about PrEP, and optimum ways to present PrEP accurately to identify those women at greatest need with greatest interest in using PrEP is about to begin in Mysore.
Research ethics: All study materials will be submitted for approval by the institutional review boards of Durbar Mahila Samanwaya Committee (DMSC) Ethical Committee, the World Health Organization (WHO) Ethics Review Committee (ERC), the University of Manitoba (UM) Health Research Ethics Board (HREB), and by the Indian Council on Medical Research (ICMR) through the Health Ministry's Screening Committee (HMSC). The procedures, risks, and benefits of study participation will be explained to all potential study participants and informed consent will be obtained from those who are willing to participate prior to their participation in the study. The project will follow all guidelines for human subjects research as mandated by the Government of India, as this is the location of the proposed project. In addition to this, a Data Safety and Monitoring Board will be established at Ashodaya to monitor the safety of participants and the scientific integrity of the study across all study sites.
Community advisory board (CAB): A community advisory board will be set up in each study site, and will meet regularly to inform study staff and the DSMB of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner.
Data Safety and Monitoring Board (DSMB): A DSMB will be established to ensure that the rights of all study participants from each site, Ashodaya and DMSC, are safeguarded, and to monitor their safety by scrutinizing any adverse events. They will also respond to concerns raised by the CABs from each site. The DSMB will include an ethicist, a human rights lawyer, representatives from the University of Manitoba, WHO and UNAIDS, representatives from the global network of sex workers, and a statistician.
- Conditions
- HIV Infection
- Being tested
- Truvada
- Keywords
- HIV, AIDS, India, Prevention, Female sex workers, PrEP, Pre-exposure prophylaxis, Truvada, Tenofovir
- Medical subject headings
- HIV Infections, Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TruvadaDrug
Also called emtricitabine and tenofovir disoproxil fumarate
The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
| Study group | Role | What they receive |
|---|---|---|
| Truvada | Experimental | Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP. Receives: Drug: Truvada |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sustained uptake and adherence to oral PrEP among female sex workers
We will assess the acceptability and feasibility of two approaches to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up. Study staff will measure PrEP initiation, adherence and discontinuation. They will record these events in participant records, and quarterly visits will be used to assess adherence through biological tests and questionnaires. PrEP will be delivered as part of a package of HIV prevention services, and therefore use of other prevention strategies, such as condom use, will also be monitored. Data on drug adherence and condom use will be collected through various means. An ethnographic study will be designed to understand factors that may promote or impede adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In addition to this, peer educators will use a pictorial tool to document these items (e.g., frequency and patterns of sexual activity, condom use, and PrEP use).
Measured: 24 months
Secondary outcomes (3)
Identification of female sex workers willing to take PrEP
We propose to develop and use of a risk screening tool to identify female sex workers who are most vulnerable to HIV. This tool will guide recruitment into the demonstration study and could later assist health providers in deciding who will benefit most from PrEP for HIV prevention. In addition, this study will assess the proportion of FSWs identified by the risk screening tool who are willing to take PrEP. Quantitative and qualitative evaluations will identify factors related to the decision to initiate PrEP as well as reasons why FSWs decline PrEP
Measured: 18 months after study commencement
Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers
The most common side effects of FTC/TDF are minor and short-lived (i.e. first several weeks). Quarterly clinic visits will assess physical health, side effects, adverse events and any other social harms or concerns with PrEP use. This study will invest in continuous engagement with communities of female sex workers according to good participatory practice guidelines to provide correct information about PrEP, keep communities continuously engaged, and maintain adherence to PrEP. A community advisory board (CAB) and a Data Safety and Monitoring Board (DSMB) will be set up. The CAB will meet monthly and on an as needed basis. The DSMB will be set up to ensure that the rights of the study participants are safeguarded in a transparent fashion, and to monitor their safety by scrutinizing any adverse events.
Measured: 24 months
Effective delivery of oral HIV PrEP demonstrated in context of National Targeted Interventions
This study proposes to deliver PrEP within the context of the National Program of Targeted Interventions in order to demonstrate that PrEP is feasible in "real world" settings. DMSC and Ashodaya currently implement targeted intervention programs for female sex workers in Kolkata and Mysore/Mandya, respectively. These programs provide outreach by peer educators and outreach workers, clinic services (e.g. HIV testing and counseling, STI screening and treatment), and referrals for HIV care and treatment for brothel- and street-based FSWs. This study will evaluate the addition of PrEP to this existing service delivery model. It will also show willingness of participants to enroll in a demonstration study and to use oral PrEP without reimbursements or incentives for participation.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2014 (estimated)
- Study startJan 2016
- Primary completion30 Apr 2018
- Study completion30 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionStudies of the same condition, open and under way.
- More trials run by University of ManitobaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,325 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Collaborators
- World Health Organization, DMSC, Ashodaya Samithi
- Responsible party
- Sponsor
- Investigators
- Sushena Reza-Paul, MBBS, Principal investigator, University of Manitoba, Ashodaya SamithiSmarajit Jana, MBBS, Principal investigator, DMSC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02148094
- Sponsor's protocol ID
- B2014:050
- Acronym
- PrEP-India
- Status last verified
- Oct 2016
- First submitted
- 22 May 2014
- Last updated
- 11 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India
- ClinicalTrials.gov ID
- NCT02148094
- Acronym / sponsor ID
- PrEP-India / B2014:050
- Conditions
- HIV Infection
- Keywords
- HIV, AIDS, India, Prevention, Female sex workers, PrEP, Pre-exposure prophylaxis, Truvada
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,325 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Collaborators
- World Health Organization, DMSC, Ashodaya Samithi
- Study start
- Jan 2016 (actual)
- Primary completion
- 30 Apr 2018 (actual)
- Study completion
- 30 Jun 2018 (actual)
- First posted
- 28 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Female sex workers (FSWs) in India are at high risk of HIV infection, and while correct and consistent condom use is an effective means of preventing HIV transmission, many FSWs have difficulty insisting on their use. Alternative HIV prevention options are needed for FSWs who are unable to correctly and consistently use condoms with their clients or regular partners. Oral pre-exposure prophylaxis (PrEP) may be an important tool to fill this critical prevention gap, and a demonstration project is required to assess the impact and feasibility of the use of PrEP as an HIV prevention intervention among most at risk FSWs in India.
The proposed project will take place at two sites in India and will assess the use of a risk assessment tool to identify FSWs who would most benefit from PrEP, collect information about the reasons why FSWs choose to accept or decline PrEP, evaluate two different PrEP delivery strategies (weekly clinic pick-up or home delivery by peer educators every second day), monitor adherence to and discontinuation of PrEP, and evaluate unintended consequences of the use of PrEP in these communities (e.g. reduction of condom use, drug side effects or adverse events, social harms or resistance). To ensure the safety of study participants, a community advisory board will be set up and will meet regularly to inform study staff of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner. A data safety and monitoring board will also be established to monitor participant safety.
Detailed description
This PrEP demonstration study is designed to assess the feasibility and impact of delivering PrEP in addition to the existing package of HIV prevention interventions available to female sex workers in India. The study aims to: 1) identify female sex workers in need of HIV prevention and willing to take PrEP; 2) evaluate sustained uptake and adherence to oral PrEP; 3) assess safe delivery of PrEP; and 4) demonstrate effective delivery of PrEP within the context of the National Program of Targeted Interventions. The study will be implemented in two regions and among two typologies of female sex workers in India: brothel-based FSWs in Kolkata and FSWs operating from different settings in Mysore and Mandya.
Outcome 1: Identification of female sex workers in need of HIV prevention and willing to take oral PrEP For optimal delivery with limited resources, it is critical to provide HIV prevention strategies such as PrEP to populations at greatest risk of infection. Female sex workers are an important population for HIV prevention in India, prioritized as a "core high risk group" for targeted interventions by the India National AIDS Control Organization (NACO) (NACO 2013 annual report). In particular, some FSWs report inconsistent condom use and have unmet needs for HIV prevention (Ramesh, 2010; Reza-Paul, 2008). For example, these women may be less empowered or able to consistently demand condom use by their clients or may wish to become pregnant. PrEP has the potential to be an additional, more acceptable and effective HIV prevention method for female sex workers who have difficulty using condoms consistently.
This study proposes the development and use of a risk screening tool to identify female sex workers who are most vulnerable to HIV. This tool will guide recruitment into the demonstration study and could later assist health providers in deciding who will benefit most from PrEP for HIV prevention. In addition, this study will assess the proportion of FSWs identified by the risk screening tool who are willing to take PrEP. Quantitative and qualitative evaluations will identify factors related to the decision to initiate PrEP as well as reasons why FSWs decline PrEP.
Outcome 2: Sustained uptake and adherence to oral PrEP among female sex workers Similar to all medications, sustained uptake and adherence to PrEP is fundamental for efficacy in preventing HIV acquisition. In the four clinical trials of oral PrEP that demonstrated efficacy, study participants with high adherence had the greatest protection from HIV (Baeten 2012, Choopanya 2013, Grant 2010, Thigpen 2012). Likewise, across PrEP trials, there was a clear relationship between higher efficacy and a greater proportion of participants with study drug detectable in their blood. Two randomized clinical trials of daily oral PrEP among heterosexual women in Africa found no efficacy for HIV prevention; poor adherence to PrEP most likely explains these results (Marrazzo 2013, Van Damme 2012). For example, drug level testing in the FEM-PrEP Study found that less than 40% of a random sample of HIV negative women in the PrEP arm of the study had detectable levels of PrEP in their blood (Van Damme 2012). Analyses of high-risk subgroups of study participants in the Partners PrEP Study found PrEP efficacy estimates ranged from 64 to 84%, showing consistently high efficacy of PrEP in preventing HIV across various higher risk groups, including women (Murnane 2013).
Preliminary community awareness campaigns for PrEP among female sex workers in Kolkata found high interest in PrEP - approximately 80% reported willingness to take daily, oral PrEP. Sex workers in Mysore-Mandya are engaged in series of consultations where information related to PrEP as a tool for combination prevention is being discussed and questions or concerns related to PrEP addressed. In both places, initial observations show that there are some sex workers (e.g. those who are on long time contracts, those with overnight clients where sometimes the number of clients are not disclosed, those who want to be pregnant, and those who do not use condoms with their regular partners) expressed interest in being part of the demonstration project.
This PrEP demonstration study will assess the acceptability and feasibility of two approaches to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up. Study staff will measure PrEP initiation, adherence and discontinuation. They will record these events in participant records, and quarterly visits will be used to assess adherence through biological tests and questionnaires. PrEP will be delivered as part of a package of HIV prevention services, and therefore use of other prevention strategies, such as condom use, will also be monitored. The full package of prevention services will continue to be provided to FSWs with the support of India's national government and in accordance with national guidelines.
Data on drug adherence and condom use will be collected through various means. An ethnographic study will be designed to understand factors that may promote or impede adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In addition to this, peer educators will use a pictorial tool to document these items (e.g., frequency and patterns of sexual activity, condom use, and PrEP use). The study will also include a biological measure of PrEP adherence through the assessment of drug-levels in the blood.
Regular counselling about HIV prevention and PrEP will be provided to study participants to promote adherence. In a sub-sample of study participants, an electronic adherence monitoring device to measure and promote adherence, Helping Hands, will be tested (De Blaser 2010). The Helping Hands device is complimented by a web platform that illustrates patient-specific data to monitor dosing history and adherence patterns.
Outcome 3: Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers Four randomized controlled trials have demonstrated that daily, oral PrEP is safe for HIV-uninfected women in a wide range of settings; these antiretrovirals have been proven safe for HIV-infected women for many years of use. The most common side effects of FTC/TDF are minor and short-lived (i.e. first several weeks). This study will provide evidence for the safe delivery of oral PrEP to female sex workers in brothel and street-based settings in India. Quarterly clinic visits will assess physical health, side effects, adverse events and any other social harms or concerns with PrEP use. This study will invest in continuous engagement with communities of female sex workers according to good participatory practice guidelines to provide correct information about PrEP, keep communities continuously engaged, and maintain adherence to PrEP.
A community advisory board (CAB) and a Data Safety and Monitoring Board (DSMB) will be set up. The CAB will meet monthly and on an as needed basis. It will inform study staff of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner. The CAB members will be close to the community and will be able to respond to community concerns by calling meetings to address issues in a timely manner. The DSMB will be set up to ensure that the rights of the study participants are safeguarded in a transparent fashion, and to monitor their safety by scrutinizing any adverse events. The DSMB will also help to respond to concerns raised by the CAB. The DSMB will include an ethicist, a human rights lawyer, representatives from University of Manitoba, WHO and UNAIDS, representatives from the global network of sex workers, and a statistician. In addition, ongoing qualitative research and monitoring by research staff, as well as outreach by peer educators, will attempt to identify any community resistance, rumours or actual harms, and respond in an appropriate manner.
Outcome 4: Effective delivery of oral HIV PrEP demonstrated in context of National Program of Targeted Interventions This study proposes to deliver PrEP within the context of the National Program of Targeted Interventions in order to demonstrate that PrEP is feasible in "real world" settings. DMSC and Ashodaya currently implement targeted intervention programs for female sex workers in Kolkata and Mysore/Mandya, respectively. These programs provide outreach by peer educators and outreach workers, clinic services (e.g. HIV testing and counseling, STI screening and treatment), and referrals for HIV care and treatment for brothel- and street-based FSWs. This study will evaluate the addition of PrEP to this existing service delivery model. It will also show willingness of participants to enroll in a demonstration study and to use oral PrEP without reimbursements or incentives for participation.
Study findings can inform national and local government's decision to adopt PrEP as a new HIV prevention strategy. Development of HIV prevention packages, provider training, quality management and service delivery guidelines in line with national systems will provide guidance for real life implementation of PrEP, and also contribute to the larger goal of providing standards for the delivery of HIV prevention interventions.
Risk Mitigation Identification of willing participants: The development of a tool to correctly identify those FSWs at continued risk of HIV infection does not ensure that those women will be willing to take PrEP. Though initial interest in PrEP is strong in Sonagachi among FSWs in general, women at highest risk may be different. A feasibility study to identify levels of awareness about PrEP, perceptions and misconceptions about PrEP, and optimum ways to present PrEP accurately to identify those women at greatest need with greatest interest in using PrEP is about to begin in Mysore.
Research ethics: All study materials will be submitted for approval by the institutional review boards of Durbar Mahila Samanwaya Committee (DMSC) Ethical Committee, the World Health Organization (WHO) Ethics Review Committee (ERC), the University of Manitoba (UM) Health Research Ethics Board (HREB), and by the Indian Council on Medical Research (ICMR) through the Health Ministry's Screening Committee (HMSC). The procedures, risks, and benefits of study participation will be explained to all potential study participants and informed consent will be obtained from those who are willing to participate prior to their participation in the study. The project will follow all guidelines for human subjects research as mandated by the Government of India, as this is the location of the proposed project. In addition to this, a Data Safety and Monitoring Board will be established at Ashodaya to monitor the safety of participants and the scientific integrity of the study across all study sites.
Community advisory board (CAB): A community advisory board will be set up in each study site, and will meet regularly to inform study staff and the DSMB of any concerns that the community may have related to the study, so that the study staff can respond in a timely manner.
Data Safety and Monitoring Board (DSMB): A DSMB will be established to ensure that the rights of all study participants from each site, Ashodaya and DMSC, are safeguarded, and to monitor their safety by scrutinizing any adverse events. They will also respond to concerns raised by the CABs from each site. The DSMB will include an ethicist, a human rights lawyer, representatives from the University of Manitoba, WHO and UNAIDS, representatives from the global network of sex workers, and a statistician.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Truvada | Experimental | Drug: TruvadaParticipants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP. |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Self-identification as a current FSW
- Age 18 and older
- Self-reported interest in and willingness to take PrEP
- Score cutoff on risk screening tool / PrEP indication tool
- HIV-negative test at time of enrollment (per testing algorithm)
Key exclusion criteria (2 listed)
- Under 18
- Does not meet inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TruvadaAlso: emtricitabine and tenofovir disoproxil fumarateThe demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites. | Drug | Truvada |
Primary outcome
Sustained uptake and adherence to oral PrEP among female sex workers
Time frame: 24 months
We will assess the acceptability and feasibility of two approaches to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up. Study staff will measure PrEP initiation, adherence and discontinuation. They will record these events in participant records, and quarterly visits will be used to assess adherence through biological tests and questionnaires. PrEP will be delivered as part of a package of HIV prevention services, and therefore use of other prevention strategies, such as condom use, will also be monitored. Data on drug adherence and condom use will be collected through various means. An ethnographic study will be designed to understand factors that may promote or impede adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In addition to this, peer educators will use a pictorial tool to document these items (e.g., frequency and patterns of sexual activity, condom use, and PrEP use).
3 secondary outcomes
Identification of female sex workers willing to take PrEP
Time frame: 18 months after study commencement
Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers
Time frame: 24 months
Effective delivery of oral HIV PrEP demonstrated in context of National Targeted Interventions
Time frame: 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Oct 2018.
- Individual participant dataSharing planned: No
Related trials for HIV Infection
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sushena Reza-Paul, MBBS principal investigator
University of Manitoba, Ashodaya Samithi
Smarajit Jana, MBBS principal investigator
DMSC
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Truvada in people with HIV Infection, run by University of Manitoba at 2 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sustained uptake and adherence to oral PrEP among female sex workers (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2018.